E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma) |
|
E.1.1.1 | Medical condition in easily understood language |
Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012818 |
E.1.2 | Term | Diffuse large B-cell lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective at Stage 1 is to: 1. Examine the safety and toxicity profile of acalabrutinib in combination with R-CHOP and define the dose limiting toxicity (DLT) or maximum administered dose (MAD).
The primary objective at Stage 2 is to: 2. To document the anti-tumour activity of acalabrutinib in combination with R-CHOP in patients with previously untreated CD20 positive DLBCL. 3. To determine additional safety information on acalabrutinib in combination with R-CHOP.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary and Tertiary objectives
Secondary Objectives
1. To determine the pharmacokinetic (PK) profile of acalabrutinib when given in combination with R-CHOP in patients with DLBCL.
2. To evaluate the effect of acalabrutinib in combination with R-CHOP on outcomes according to cell of origin.
3. To measure the duration of response to acalabrutinib in combination with R-CHOP over a follow-up period of 2 years.
Tertiary Objectives
4. To determine BTK occupancy by acalabrutinib in peripheral blood mononuclear cells when given in combination with R-CHOP.
5. To determine BTK occupancy by acalabrutinib in tumour material taken 8 days after initiation of therapy when acalabrutinib is given in combination with R-CHOP (optional).
6. To determine the impact of the addition of acalabrutinib on R-CHOP mediated antibody dependent cellular cytotoxicity (ADCC).
7. To determine evidence of B-cell receptor activation (BCR) in patients before and after treatment with R-CHOP and acalabrutinib.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed DLBCL, expressing CD20. Sufficient diagnostic material should be available to forward to a central laboratory for gene expression profiling and pathology review 2. Measurable disease of at least 15mm 3. Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent 4. Stage IAX (bulk defined as lymph node diameter >10cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease are not eligible 5. ECOG performance status 0-2 or 3 if this is directly attributable to lymphoma 6. Adequate bone marrow function with platelets > 100x109/L; neutrophils > 1.0x109/L at study entry, unless lower figures are attributable to lymphoma 7. Measured or calculated creatinine clearance > 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) x Mass (kg)x(1.04 (for women)or 1.23 (for men))/Serum Creatinine (umolL)] 8. Serum bilirubin < 35μmol/L and transaminases < 2.5x upper limit of normal at time of study entry 9. Cardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram or MUGA is required to establish baseline LVEF equal to or greater than 55% 10. No concurrent uncontrolled medical condition 11. Life expectancy > 3 months 12. Aged 16 years or above 13. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty 14. Ability to understand the purpose and risks of the study and provide signed and dated informed consent
|
|
E.4 | Principal exclusion criteria |
1. Previous history of treated or untreated indolent lymphoma. However newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible 2. Patients who have received immunisation with a live vaccine within four weeks prior to enrolment will be ineligible 3. Diagnosis of primary mediastinal lymphoma 4. Diagnosis of primary Central Nervous System lymphoma. 5. History of stroke or intracranial haemorrhage in preceding 6 months 6. History of bleeding diathesis (eg. haemophilia, von Willebrand disease) 7. Requires or receiving anticoagulation with warfarin or equivalent antagonists (eg. phenprocoumon) within 7 days of first dose of acalabrutinib. However patients using therapeutic low molecule weight heparin or low dose aspirin will be eligible 8. Prior exposure to a BCR inhibitor(eg. BtK inhibitors, phosphoinositide-3 kinase (PI3K), or SyK inhibitors) or BCL-2 inhibitor (eg. ABT-199) 9. Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer 10. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to short-acting H2-receptor antagonists or antacids are eligible for enrolment into this study. 11. Uncontrolled systemic infection 12. Major surgery in the preceding 4 weeks of first dose of study drug. If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug 13. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec at screening. 14. Serological positivity for Hepatitis B, C, or known HIV infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy. - Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible. - Positive test results for hepatitis C virus (HCV) antibody serology will not be eligible. 15. Women who are sexually active and can bear children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 4.7 16. Breastfeeding or pregnant 17. Men who are sexually active and can potentially father children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of acalabrutinib. Highly effective forms of contraception are defined in Section 4.7 18. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of study drug. 19. Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent 20. Prior malignancy (other than DLBCL), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years. Note: these cases must be discussed with SCTU 21. Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction or gastric restrictions and bariatric surgery, such as gastric bypass 22. Any immunotherapy within 4 weeks of 1st dose of the study 23. Concurrent participation in another therapeutic clinical trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Dose limiting toxicity of acalabrutinib combined to R-CHOP
2. Overall response rate of the combination acalabrutinib and R-CHOP
3. Safety of the combination acalabrutinib and R-CHOP |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
For eligible patients AE collection and monitoring commences from the time the patient gives their written consent to participate in the trial and continues for two years after the last administration of acalabrutinib.
A CT scan (potentially bone marrow) at the end of therapy visit and continued monitoring through follow up will be used to assess overall response.
Follow up of AEs with a causality of possible, probable or highly probable will continue until the events resolve, stabilise or the patient starts another anticancer therapy. |
|
E.5.2 | Secondary end point(s) |
1. Pharmokinetic of acalabrutinib, AUC, Cmax, Tmax, half-life T1/2 and other PK parameter.
2. Overall response rate of the combination acalabrutinib and R-CHOP according cell of origin
3. 2-years progression-free survival; 2 years overall survival.
4. BTK occupancy by acalabrutinib on peripheral blood (PBMC) using fluorescent affinity probe assay.
5. BTK occupancy by acalabrutinib in repeat tumour core biopsy using a fluorescent affinity probe assay.
6. Antibody-dependent cell-mediated cytotoxicity (ADCC) of R-CHOP when combined to acalabrutinib, post 1st R-CHOP and at day 8, 2nd cycle acalabrutinib + R-CHOP.
7. CD86 and CD69 expression as a function of BCR activation by flow cytometry.
8. Tumour-specific DNA in plasma will be sequenced throughout treatment and compared with lymphoma tissue and clinical course
9. Apply the following techniques to FFPE tumour material: mutational panel, FISH analysis, immunohistochemical analysis for dual protein expression of Myc and Bcl2 and gene expression |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. PK samples: cycle 2 days 1, 8, 15; cycle 3 day 1;
2. Gene expression analysis on original biopsy sample.
3. Disease assessments at baseline, end of therapy visit, then 1 & 2 years post-treatment.
4. BTK occupancy in PBMCs: cycle 2 days 1 and 8.
5. Option ultrasound guided needle biopsy or fine needle aspirate at baseline and on cycle 2 day 8.
6. ADCC assay performed at cycle 2 days 1 and 8.
7. CD86 and CD69 expression: cycle 2 days 1, 8 and cycle 4 day 1.
8. Streck Plasma DNA Sample: Baseline, cycle 2 day 1, cycle 3 day 1, end of treatment and follow up visits 3, 6, 9, 12, 16, 20 and 24
9. Tests on baseline tumour sample. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. The end of the trial is defined as: The patient reaches the final follow up visit, which will be 2 years after receiving the last study treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 3 |